Compare BridgeBio Pharma Inc (BBIO) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Linde PLC — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Linde PLC trades at $521.43 (market cap $241.59B). The key difference: Linde PLC is far larger — about 14.7× BridgeBio Pharma Inc's market cap, and Linde PLC pays a 1.22% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LIN | |
|---|---|---|
Market Cap | $16.46B | $241.59B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $546.64 |
52-Week Low | $44.81 | $389.38 |
Enterprise Value | $18.02B | $263.95B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Linde (LIN) trades at $522.54, down 1.37% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $560. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a net income margin of 20.44%. Recent news highlights sustainability leadership and strategic growth, though valuation ratios like a P/E of 34.75 suggest premium pricing.
The stock offers steady growth potential driven by earnings beats and dividend consistency, but faces risks from rising debt levels and macroeconomic pressures. Analyst sentiment is overwhelmingly bullish with 85.7% buy ratings, indicating confidence in Linde's operational strength and future performance, though investors should monitor debt trends and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
